Liminal BioSciences is a global clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases with a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada,  and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market (LMNL).

On October 15, 2021 the Company closed on the divestment of the remainder of its plasma-derived therapeutics business to focus solely on its small molecule therapeutics pipeline.

 

Subscribe here to receive Liminal's latest news by email.     

Recent News
Jun 6, 2022
Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 6,...

May 23, 2022
Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in the Company's Phase 1a single ascending dose ("SAD")...

May 10, 2022
Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple...

Webcasts
Jefferies Investor Conference
Thursday, June 9, 2022
2:00pm EDT
H.C. Wainwright Investor Conference
Tuesday, May 24, 2022
2:30pm EDT
Stock Quote
NASDAQLMNL